The wait is over…well, kind of. Last week the Food and Drug Administration (FDA) released its guidelines for the approval pathway of biosimilar drugs to be introduced in the U.S.

A “national moment of truth.”  That’s how President Obama’s fiscal reform commission characterized the state of the nation’s finances over one year ago.  Last year, the President kicked the commission’s bipartisan proposals into the gutter, put out a budget drenched in red ink, and was greeted with such outrage that he quickly gave speech tha